About European Vaccine Manufacturers
Mission
- To create a supportive environment for improved vaccine
protection and coverage in the interest of individual and community
public health.
- To promote vaccine R & D to meet new challenges
for innovative vaccine applications against infectious and other types
of diseases.
- To foster a favourable policy climate for the vaccine
industry in Europe to bring new vaccines to the world.
EVM membership
EVM structure
EVM is governed by a General Assembly, meeting once
a year, that comprises two representatives of each member company; and
an EVM Board, elected by the General Assembly, that defines EVM strategy
and policies in line with EFPIA policies.
The EVM Board is made up of the following members:
| Officers:
- President - Didier Hoch (Sanofi Pasteur MSD)
- Treasurer - Jacques Berger (Sanofi Pasteur)
Members
- Denis Cavert (Baxter)
- Patrick Florent (GlaxoSmithKline)
- Markus Leyck Dieken (Novartis Vaccines)
- Björn Sjöstrand (Crucell)
- Herman van Heemstra (Solvay Biologicals)
Working Group Chairpersons
- Bernard Fritzell (Wyeth)- Chair of Clinical and R&D Working Group
- Bernadette Hendrickx (Sanofi Pasteur) - Chair of Regulatory Working Group
- Luc Hessel (Sanofi Pasteur MSD) - Chair of Influenza Pandemic working group
- Ian Kingston (GSK) - Chair of Public Health Policy Working
Group
|
 |
EVM Working Groups
EVM Working Groups report to the EVM Board, and comprise
experts from the following areas:
- Clinical and R&D
- Influenza Pandemic
- Public health
- Regulatory affairs
Did you know that the European vaccine industry:
- is the largest supplier of vaccines in the
world, producing the majority of vaccine doses in Europe
- is the largest supplier to UNICEF of vital paediatric
vaccines,including polio vaccines
- has developed vaccines specifically designed for
the needs of developing countries (e.g., combined paediatric vaccines
against diphtheria, tetanus, pertussis, hepatitis B, and invasive Hib
disease)
- is working in collaboration with the public sector
in joint R&D activities and in clinical trials partnerships to develop
vaccines against diseases that particularly burden developing countries
(e.g., denguefever, leishmaniasis, rotavirus, HIV, malaria and tuberculosis,
among others)
- contributes significantly to Research & Development
with over half of all global vaccine R&D being carried out in Europe
by EVM member companies
- has production facilities not only in Europe but
across the globe through international collaboration and joint ventures
- submits its novel products to a centralised procedure
to obtain EU licensing (e.g. all hepatitis B vaccines, hepatitis B-containing
combination vaccines, as well as the pneumococcal conjugate vaccines,
among others).
©European Vaccine Manufacturers (EVM) - a specialised group of EFPIA 2007
|
